-
Roth Remains Positive on Aduro Biotech (ADRO) Upon Start of SEASCAPE Trial; Affirms at 'Buy'
-
Roth Remains Positive on Aduro Biotech's (ADRO) CRS-207 ECLIPSE Outcome; Reaffirms at 'Focus Pick'
-
Current Valuation on Aduro Biotech (ADRO) Doesn't Appreciate Upcoming Opportunities - Roth Capital
-
Aduro Biotech (ADRO) Added to Focus List at Roth Capital
-
Streetinsider.com's Hot Lunchtime Reads 11/24: (ADRO) (IMPV) (AAPL) (LLL)
-
Aduro Biotech (ADRO) Adverse Event was Protocol Violation, Roth Capital Says; Sees Sell-Off as Overreaction
-
Roth Trims PT on Aduro BioTech (ADRO) to $68; Notes Several Catalysts for FY16
-
Roth Capital Reiterates Buy on Aduro Biotech (ADRO) Following Announced Incyte (INCY) Collaboration
-
Roth Capital Highlights Biotech Picks 'for the Turn' and Over the Long Haul (PTN) (LGND) (TGTX) (CLDX)
-
Roth Capital Reiterated Bullish Stance on Aduro Biotech (ADRO) Following ASCO Abstracts
-
Roth Affirms Aduro Biotech (ADRO) at 'Buy'; Novartis' (NVS) Data Validates Mesothelin CAR-T
-
Pre-Open Stock Movers 4/20: (HQCL) (ADRO) (HAS) Higher; (AMPE) (FARO) (RCL) Lower (more...)
-
UPDATE: Roth Capital Starts ADURO BIOTECH (ADRO) at Buy, PT $74

